Etodolac
Code | Size | Price |
---|
TAR-T1002-25mg | 25mg | £98.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1002-50mg | 50mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1002-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1002-100mg | 100mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1002-200mg | 200mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Etodolac inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. Etodolac is a pyranocarboxylic acid and non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activities. It also inhibits platelet aggregation by blocking platelet cyclooxygenase and the subsequent formation of thromboxane A2.
CAS:
41340-25-4
Formula:
C17H21NO3
Molecular Weight:
287.359
Pathway:
Metabolism; Immunology/Inflammation; Neuroscience
Purity:
0.9992
SMILES:
CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12
Target:
Retinoid Receptor; COX
References
1. Kumagai K, et al. Int J Mol Sci,2013, 14(10), 19705-19715.
2. Ito S, et al. J Pharmacol Exp Ther,2012, 342(1), 53-60.
3. Tachibana M, et al. Pharmacology,2003, 68(2), 96-104.
4. Magari H, et al. Biochem Biophys Res Commun,2005, 334(2), 606-612.
5. Suyama H, et al. Brain Res,2004, 12010(1-2), 144-150.